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OBJECTIVE—Impaired insulin-dependent glucose disposal in
muscle and fat is a harbinger of type 2 diabetes, but murine
models of selective insulin resistance at these two sites are
conspicuous by their failure to cause hyperglycemia. A deﬁning
feature of muscle and fat vis-à-vis insulin signaling is that they
both express the insulin-sensitive glucose transporter Glut4. We
hypothesized that diabetes is the result of impaired insulin sig-
naling in all Glut4-expressing tissues.
RESEARCH DESIGN AND METHODS—To test the hypoth-
esis, we generated mice lacking insulin receptors at these sites
(“GIRKO” mice), including muscle, fat, and a subset of Glut4-
positive neurons scattered throughout the central nervous
system.
RESULTS—GIRKO mice develop diabetes with high frequency
because of reduced glucose uptake in peripheral organs, exces-
sive hepatic glucose production, and b-cell failure.
CONCLUSIONS—The conceptual advance of the present ﬁnd-
ings lies in the identiﬁcation of a tissue constellation that melds
cell-autonomous mechanisms of insulin resistance (in muscle/fat)
with cell-nonautonomous mechanisms (in liver and b-cell) to
cause overt diabetes. The data are consistent with the identiﬁca-
tion of Glut4 neurons as a distinct neuroanatomic entity with
a likely metabolic role. Diabetes 60:700–709, 2011
T
ype 2 diabetes (T2D) can be viewed as a failure
of homeostatic mechanisms that promote nu-
trient turnover and storage in response to hor-
monal cues. Although the factors that favor
disease progression are heterogeneous, evidence from
prospective human studies indicates that impairment of
insulin-dependent glucose uptake and utilization is an
early event in disease pathogenesis (1). The largest frac-
tion of insulin-dependent glucose disposal (;70%) occurs
in skeletal muscle and is mediated by the insulin-responsive
glucose transporter Glut4 (2). A quantitatively smaller con-
tribution (5–20%) is provided by adipose tissue (3). That
skeletal muscle is an important site of insulin resistance in
humans and that impaired insulin action in muscle leads
to adaptive changes in nutrient use from carbohydrates to
lipids and to compensatory b-cell hyperplasia are beyond
dispute (4). Similarly, insulin resistance in adipose tissue
is contributory to the pathogenesis of diabetes not only
through impaired glucose disposal but also through excess
lipolysis and adipokine/cytokine production (5). But
models of muscle/fat insulin resistance, such as those
generated by targeted inactivation of insulin receptor
(InsR) (6–8) or the insulin-responsive glucose transporter
Glut4 (9) in those tissues, have limited metabolic conse-
quences and do not result in overt diabetes. One possible
explanation is that an independent “hit” on the pancreatic
b-cell is required, leading to reduced insulin secretion or
curtailing b-cell hyperplasia in response to insulin resis-
tance (10,11). Alternatively, these data can be construed to
suggest that the transition from compensated insulin re-
sistance to overt diabetes requires impairment of insulin
action at additional sites (12).
Insulin signaling in the central nervous system (CNS)
affects systemic insulin sensitivity and glucose metabolism
(13–16). It is intriguing that Glut4 is also expressed in
discrete brain regions, where its levels are increased in
murine models of T2D and decreased in streptozotocin-
induced diabetes (17–20). The contribution of CNS Glut4
to insulin action and glucose homeostasis remains unclear,
because Glut4-positive cells express additional glucose
transporters (e.g., Glut3) whose contribution to over-
all glucose uptake likely dwar f st h a to fG l u t 4( 2 1 ) .A l s o ,
the brain as a whole metabolizes glucose in an insulin-
independent manner (22).
In addition to the important role of Glut4 in insulin-
dependent glucose uptake, its expression in tissues that do
not require insulin for glucose uptake (e.g., CNS) might
represent a vestigial marker of tissue insulin responsive-
ness independently of the actual role of Glut4 proper in
glucose uptake, and a generalized impairment of insulin
action in all Glut4 tissues might underlie the pathogenesis
of diabetes. Accordingly, we set out to generate a murine
model of impaired insulin signaling in Glut4-expressing
tissues. In doing so, the driving hypothesis was that the
cause for the absence of diabetes in murine models of
muscle/fat insulin resistance is the preservation of insulin
signaling in other insulin-sensitive tissues (as character-
ized by Glut4 expression), and primarily in Glut4 neurons
of the CNS. To test this hypothesis, we engendered insulin
resistance in Glut4-expressing tissues by targeted inacti-
vation of InsR and performed metabolic analyses of the
resulting phenotypes.
RESEARCH DESIGN AND METHODS
DNA constructs and experimental animals. A DNA construct encoding
GLUT4-Cre was engineered by cloning a 2.4-kb human GLUT4 promoter
fragment (23) into pSP73 vector, containing Cre cDNA preceded by a b-globin
intron. The puriﬁed linearized DNA fragment was microinjected into fertilized
eggs from C57BL/6 3 FVB mice. We obtained two founders (535 and 546) that
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ORIGINAL ARTICLEwere characterized for transgene transmission and recombination. The
transgene showed autosomal transmission in line 546 and X-linked trans-
mission in line 535. Both lines underwent germ line recombination when
transmitted through the dam, but not when transmitted through the sire. When
transmitted through the sire, both transgenes were liable to stochastic em-
bryonic activation, leading to generation of animals with varying degrees of
chimerism. An example is shown in Supplementary Fig. 1, demonstrating
chimeric recombination in liver of GIRKO mice. These events were monitored
by genotyping of tail DNA, and chimeric mice were excluded from further
analyses. When mice were killed, extensive genotyping was performed to
ascertain that mice had undergone recombination only in bona ﬁde Glut4-
expressing tissues.
Line 546 transgenics were intercrossed with Insr
ﬂox/ﬂox mice (7), and
the resulting progeny was intercrossed to yield Insr
ﬂox/ﬂox controls and
Insr
ﬂox/ﬂox, GLUT4-cre (GIRKO) mice that were used for all subsequent pheno-
typic analyses. Animals were maintained on a mixed background derived from
129/Sv, C57BL/6, and FVB. GLUT4-Cre was genotyped using primers 59-
TGGGTCCCATCGGGCCCTTAATT-39 and 59-TGGCGATCCCTGAACATGTCCAT-
39, amplifying a 350-bp product in the presence of the transgene. Rosa26/Gfp and
Rosa26/Rfp mice were obtained from Jackson Laboratories. The Columbia Uni-
versity Institutional Animal Care and Utilization Committee and the Yale Uni-
versity Animal Care and Use Committee approved all animal procedures.
Metabolic analyses. Blood glucose was measured by the One-Touch Ultra
meter(LifeScan Inc.,Milpitas, CA).Insulinandleptinweremeasuredbyenzyme-
linked immunosorbent assay, and glucagon was measured by radioimmuno-
assay (Linco Research Inc., St. Charles, MO). Plasma free fatty acids (FFA) and
cholesterolweremeasuredbyNEFA-HRandCholesterol-Etestreagents(Wako
Chemicals, Richmond, VA). Triglycerides were measured by serum triglyc-
eride determination kit (Sigma-Aldrich, St. Louis, MO). b-Hydroxyl butyrate was
measured by a colorimetric assay (Pointe Scientiﬁc, Canton, MI). Measurements
of hepatic glycogen and triglycerides were performed as previously described
(24). Body composition was determined using Bruker Minispec NMR (Bruker
Optics, Billerica, MA) (16).
In vivo analysis of insulin signaling. Male mice, 12 to 14 weeks old, were
fasted overnight, anesthetized, and injected with saline or insulin (5U) into the
inferior vena cava. Three minutes after injection, muscle, adipose, liver, heart,
and brain tissues were rapidly removed and ﬂash-frozen in liquid nitrogen
(25). Detergent extracts were prepared in buffer containing 20 mmol/L Tris
(pH 7.6), 150 mmol/L NaCl, 1 mmol/L dithiothreitol, 10 mmol/L EGTA, 1% NP40,
2.5 mmol/L Na4P2O7, 1 mmol/L NaVO3, 1 mmol/L b-glycerophosphate, and pro-
tease inhibitor cocktail (Roche, Indianapolis, IN). Protein concentration of
extracts was determined by bicinchoninic acid assay (Pierce, Rockford, IL).
Equal amounts of protein (50–100 mg) were resolved on SDS-PAGE and
transferred onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH).
Membranes were probed with antibodies against phospho-Akt (Ser473), total
Akt (Cell Signaling, Danvers, MA), InsRb, and b-actin (Santa Cruz Biotech-
nology, Santa Cruz, CA).
Euglycemic-hyperinsulinemic clamps. Thirteen- to ﬁfteen-week-old nor-
moglycemic male GIRKO mice (n = 10) and control littermates (n = 9) were
studied. Euglycemic-hyperinsulinemic clamps were performed in conscious,
minimally stressed mice at the Yale Mouse Metabolic Phenotyping Center
(http://mouse.yale.edu). Brieﬂy, after anesthesia, an indwelling catheter was
placed into the right internal jugular vein. Studies were carried out 4 to 5 days
after surgery in overnight fasted mice. Tail tethered using tape and basal
glucose turnover were measured using a primed-continuous infusion of [3-
3H]
glucose for 2 h before the start of clamp. At the start of the clamp, mice re-
ceived a primed constant infusion of human insulin (15 pmol/kg/min) and
continued to receive [3-
3H]glucose (0.1 mCi/min, PerkinElmer, Waltham, MA)
FIG. 1. GLUT4-Cre–mediated recombination in the brain and Glut4 neurohistochemistry. A–D: GFP immunoreactivity (green) and Hoechst nuclear
staining (blue) in cortex (A), thalamus (B), dentate gyrus (C), and hypothalamus (D)o fGLUT4-Cre/Rosa26-Gfp mice. E, F: Immunostaining with
anti-Glut4 (red) and anti-GFP (green) antibodies in mediobasal hypothalamus of GLUT4-Cre/Rosa26-Gfp mice; F is a higher magniﬁcation view of
E, with arrows indicating Glut4-positive/GFP-negative cell bodies (left panel), arrowheads indicating GFP-positive/Glut4-negative cell bodies
(second panel from the left), and concave arrowheads indicating Glut4-positive/GFP-positive cell bodies (third panel from the left). The DNA-
counterstained merged image is shown on the right. 3V, third ventricle; ARC, arcuate nucleus. Scale bars: 100 mm( A–E) and 50 mm( F). (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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glucose was determined at 10- to 20-min intervals. Glucose (20% solution)
was infused at a variable rate as required to maintain euglycemia. 2-Deoxy-
D-[1-
14C]glucose (2-[
14C]DG) was administered as a bolus (10 mCi) 75 min
after the start of the clamp. Blood samples (20 mL) were taken at 25, 80, 85,
90, 100, 110, and 120 min of clamp for the measurement of plasma [
3H]
glucose, tritiated water, or 2-[
14C]DG concentrations. Additional blood
samples (20 mL) were collected before and at the end of clamp for the
measurement of plasma insulin and FFA. At the end of the clamp, mice were
killed, and liver, gastrocnemius, epididymal fat, and cerebral cortex were
ﬂash-frozen in liquid nitrogen. Tissue samples were stored at –80°C for
analysis (16).
Indirect calorimetry. Mice were individually housed in a TSE LabMaster
system (TSE Systems Inc., Chesterﬁeld, MO) and acclimated to the respiratory
chambers for 24–36 h before measurements were taken. Data on gas exchanges,
locomotor activity, and food intake were collected every 14 min for 4–5d a y s
(26).
Histology andimmunohistochemistry.Adipose tissue and liverwere ﬁxed in
10% formaldehyde for hematoxylin–eosin and periodic acid-Schiff staining.
Frozen liver embedded in OCT was used for Oil red O staining. Pancreata from
12-week-old male mice were ﬁxed in 10% formaldehyde overnight and em-
bedded in parafﬁn; consecutive sections 5 mm in thickness were mounted on
slides. Sections were stained with antibodies against insulin, glucagon (Sigma-
Aldrich San Antonio, TX), Pdx1 (27), and Glut2 (Alpha Diagnostics, Owings
Mills, MD) (28).
Statistical methods. All data represent means 6 SEM. Datasets were ana-
lyzed for statistical signiﬁcance with one-way ANOVA followed by post hoc
Bonferroni test using SPSS software (SPSS Inc., Chicago, IL).
RESULTS
Generation of GLUT4-Cre mice. We generated trans-
genic mice expressing Cre off a 2.4-kb GLUT4 promoter
fragment that has been shown to confer tissue-speciﬁc
expression of a reporter construct (23). We characterized
recombination patterns in two GLUT4-Cre founders (lines
535 and 546) by crossing them with either ROSA26-Gfp or
ROSA26-Rfp transgenics. Line 546 faithfully recapitulated
Glut4 expression, yielding recombination in skeletal mus-
cle, epididymal and subcutaneous white adipose tissue
(WAT) and brown adipose tissue (BAT), heart, and kidney
(glomeruli and loop of Henle). We also detected recom-
bination at sites of Glut4 expression heretofore unrecog-
nized, such as ovarian corpora lutea, myometrium, nuclear
layers of the retina, and acinar cells in the exocrine pan-
creas and salivary gland (Supplementary Fig. 1A and B).
Line 535 showed more limited recombination in skeletal
muscle and brain (not shown).
In view of literature on Glut4 expression in the CNS (17,
20,21,29,30), we analyzed patterns of GLUT4-Cre–mediated
recombination in this organ using GLUT4-Cre 3 Rosa26-Gfp
mice. Green ﬂuorescent protein (GFP) immunohistochem-
istry in brain sections of the resulting progeny revealed
Cre-mediated recombination in scattered subsets of cells
FIG. 2. Colocalization of GLUT4-Cre–mediated recombination with neuronal and glial markers. A, B: Coimmunostaining with GFP (green) and
neuronal marker HuC/D (red) antibodies in hypothalamus and cortex of GLUT4-Cre/Rosa26-Gfp mice. C, D: Coimmunostaining with GFP (green)
and glial marker Gfap (red) antibodies in hypothalamus and hippocampus of GLUT4-Cre/Rosa26-Gfp mice. Scale bars: 50 mm. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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cerebellar Purkinje-like cells, olfactory bulb, hippocam-
pus, and hypothalamus (Supplementary Fig. 2). Coim-
munostaining with either of two different anti-Glut4
antibodies and GFP in the hypothalamus of GLUT4-Cre 3
Rosa26-Gfp mice showed that .90% of GFP-positive cells
(Fig. 1A–D) were also Glut4-positive (Fig. 1E and F), dem-
onstrating that the transgene recapitulates faithfully the
expression of the endogenous gene. To characterize Glut4-
positive cells, we performed coimmunostaining with GFP
and either the neuronal marker HuC/D or the glial marker
Gfap throughout the CNS. The former, but not the latter,
colocalized with Glut4 (Fig. 2). These data indicate that
GLUT4-Cre induces recombination in a subset of neu-
rons characterized by expression of Glut4 protein. We
obtained similar data in the CNS of line 535 (data not
shown).
Generation of GIRKO mice. To generate a model of in-
sulin resistance in Glut4-cre–expressing tissues, we inter-
crossed transgenic line 546 with Insr
ﬂox/ﬂox mice (7). The
resulting Insr
ﬂox/ﬂox,GLUT4-cre mice (Glut4-cre–driven InsR
knockout, or GIRKO) showed InsR ablation in skeletal
muscle, WAT, and BAT. A measurable decrease of InsR also
could be detected in the hippocampus and mediobasal hy-
pothalamus, but not in the cortex and cerebellum (Fig. 3A
and Supplementary Fig. 5), consistent with the fact that
most cells in the former two sites are Glut4-positive,
whereas ;10% in the latter two sites are Glut4-positive
(Supplementary Fig. 2). Accordingly, insulin-stimulated
Akt phosphorylation was absent in skeletal muscle, in-
cluding soleus and gastrocnemius, WAT (subcutaneous
and epididymal), and BAT, whereas it was preserved in
liver of GIRKO mice (Fig. 3B). We obtained identical
results when we measured phospho-GSK-3 levels in
response to insulin, indicating that Akt activity is im-
paired (Supplementary Fig. 3).
GIRKO mice develop insulin-resistant diabetes. GIRKO
mice were born in the expected Mendelian ratios and
showed no gross abnormality. A subset in both sexes de-
veloped hyperglycemia in the fed state (Fig. 4A and B)a n d
hyperinsulinemia in the fed and fasted states (Supplementary
T a b l e1 ,F i g .4 C). The prevalence of diabetes (deﬁned as
glycemia . mean + 2 SD) increased from 20% at 5 weeks to
25% at 12 weeks and 46% at 24 weeks of age in male mice,
and hovered at approximately 10% in 5- to 12-week-old
female mice. Intraperitoneal glucose tolerance and insulin
tolerance tests in 12- to 13-week-old mice revealed modest
glucose intolerance in male GIRKO mice and insulin re-
sistance in female GIRKO mice, respectively (Supplementary
Fig. 4).
Glucose clamps. To probe tissue-speciﬁc glucose metab-
olism and insulin sensitivity, we performed euglycemic-
hyperinsulinemic clamps on 13- to 15-week-old non-
diabetic male GIRKO and control littermates. Under basal
conditions, blood glucose was slightly higher in GIRKO
mice than in controls (119 vs. 87 mg/dL) (Fig. 5A). During
the hyperinsulinemic phase of the clamp, we infused in-
sulin to yield a similar increase in plasma insulin between
the two groups (Supplementary Table 2) and achieved
similar blood glucose levels at steady state. The rate of
glucose infusion required to maintain euglycemia was de-
creased by 52% in GIRKO mice (Fig. 5B), consistent with
impaired glucose disposal. Basal hepatic glucose produc-
tion (HGP) was increased by 32% in GIRKO mice (Fig.
5C), and hyperinsulinemia was unable to suppress it (Fig. 5D
and E), indicating marked hepatic insulin resistance. More-
over, the rate of glucose disappearance was reduced by
28% and glycolysis by 33% in GIRKO mice compared with
FIG. 3. Insulin signaling in GIRKO mice. A: Western blot analysis of InsR expression. Loading controls are shown in Supplementary Fig. 5.
B: Insulin-dependent Akt phosphorylation in 12- to 14-week-old male normoglycemic GIRKO mice and control littermates (wild-type [WT]) after
inferior vena cava injection of insulin or saline. Images shown are representative of four independent experiments.
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trended downward (Fig. 5H). Consistent with impaired
insulin-dependent glucose uptake, 2-deoxy-glucose incor-
poration in gastrocnemius muscle was reduced by 34% in
GIRKO mice (Fig. 5I). In contrast, 2-deoxy-glucose uptake
in the cerebral cortex was not signiﬁcantly altered (Fig.
5J), consistent with the insulin-independent mode of this
process (mediated by Glut1 and Glut3) (22).
Given that hepatic insulin signaling (Fig. 3) and ex-
pression of genes encoding gluconeogenic enzymes are
normal in GIRKO mice (data not shown), the increase of
HGP is likely secondary to changes in humoral/neural fac-
tors or increased gluconeogenic precursors, such as FFA.
Fasting FFA showed a nonsigniﬁcant decrease in GIRKO
mice. Clamp hyperinsulinemia suppressed FFA by 43% in
controls, but had no effect in GIRKO mice, consistent with
reduced sensitivity of adipose tissue to insulin’s anti-
lipolytic actions (Supplementary Table 2). Fasting plasma
glucagon and b-hydroxyl butyrate levels were similar be-
tween the two groups of mice (Supplementary Table 1),
indicating that glucagon tone and fatty acid oxidation are
normal in GIRKO mice. Hepatic triglyceride and glycogen
content tended to be increased in overnight-fasted GIRKO
mice compared with wild-type mice, but these changes did
not reach statistical signiﬁcance (Supplementary Table 1).
The data suggest that failure to suppress FFA contributes
to the increased HGP observed in hyperinsulinemic con-
ditions, but cannot explain the increased basal HGP.
Morphologic analysis of BAT of 6-month-old GIRKO
mice showed increased lipid droplet size and striking dis-
ruption of the multilocular structure that were more pro-
nounced in diabetic GIRKO mice (Fig. 6A). Epididymal
WAT of diabetic and nondiabetic GIRKO mice had a het-
erogeneous appearance compared with controls (Fig. 6B),
r e m i n i s c e n to ft h ep h e n o t y p eo ff a t - s p e c i ﬁc InsR knockouts
(8). We also examined hepatic lipid and glycogen content by
Oil red O and periodic acid-Schiff staining, respectively, and
found hepatosteatosis and glycogen depletion only in di-
abetic GIRKO mice, whereas livers of nondiabetic GIRKO
mice appeared normal (Fig. 6C and D).
b-Cell compensation and failure in GIRKO mice. We
examined pancreatic islet morphology in 12-week-old
male animals. Euglycemic GIRKO mice showed b-cell hy-
perplasia but maintained normal islet architecture (Fig. 7A
and B). In contrast, diabetic GIRKO mice showed a leop-
ard patterned loss of insulin immunoreactivity (Fig. 7C)
(31), accompanied by loss of Pdx1 immunoreactivity (Fig. 7D
and E), ectopic a-cells in the islet core (Fig. 7F–H), and loss
of membrane localization of Glut2 (Fig. 7J and K).
Energy homeostasis in GIRKO mice. To determine
whether InsR ablation in Glut4-expressing tissues affected
energy homeostasis, we assessed respiratory exchanges
by indirect calorimetry, coupled with food intake and ac-
tivity determinations. GIRKO mice had normal body weight
as weanlings, but showed persistent growth retardation
thereafter, and weight of 16-week-old male mice was re-
duced by 19% compared with controls (Fig. 8A). The re-
duction in body weight affected equally lean and fat mass
and was associated with normal plasma leptin levels
(Supplementary Table 1). Diabetic GIRKO had signiﬁcantly
lower body weights than control or nondiabetic GIRKO
mice (data not shown).
Body weight in the cohort that underwent indirect cal-
orimetry determinations showed the same distribution as
in the population as a whole (Fig. 8B). Daily food intake
was similar between controls and nondiabetic GIRKO
mice (Fig. 8C), but the latter displayed altered circadian
feeding patterns, consuming only 26% of total food during
FIG. 4. Insulin and glucose levels. Scatter plots of blood glucose values in ad libitum (ad lib)-fed male (A) and female (B) WT and GIRKO
littermates at 5 and 12 weeks of age. C: Scatter plot of blood glucose vs. serum insulin levels in ad libitum-fed 12-week-old male mice.
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8D). In addition, oxygen consumption and locomotion
were largely unperturbed in nondiabetic GIRKO mice (Fig.
8E–G). In diabetic GIRKO mice, food intake was increased
when normalized by body weight (Fig. 8C), but total intake
per animal was similar to that of control and nondiabetic
GIRKO mice (Fig. 8D). In addition, although oxygen con-
sumption in diabetic GIRKO mice showed an increase
when normalized by body weight (Fig. 8E), total energy
expenditure per animal tended to decrease (Fig. 8F),
L
FIG. 5. Hyperinsulinemic euglycemic clamps. A: Blood glucose of 13- to 15-week-old male WT and GIRKO mice during the clamp studies. B: Glucose
infusion rate during the clamp. HGP during basal (C) and hyperinsulinemic (D) periods of the clamp. E: Suppression of HGP by hyperinsulinemia.
Rate of glucose disappearance (F), glycolysis (G), and glycogen synthesis (H) during the clamp. Uptake of 2-deoxyglucose (2-DOG) during the last
10 min of the clamp in gastrocnemius (I) and cerebral cortex (J). Data are mean 6 SEM. n =9 –10. *P < 0.05, **P < 0.01 vs. WT.
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locomotion (Fig. 8G). Furthermore, respiratory exchange
ratio and carbohydrate use in diabetic GIRKO mice failed
to show circadian variations, with no discernible increase
after food ingestion during the dark phase (Fig. 8H and I).
Taken together, these data indicate that InsR ablation in
Glut4-expressing neurons does not alter energy intake or
expenditure, but may affect circadian feeding patterns.
The changes seen in hyperglycemic GIRKO mice, includ-
ing metabolic substrate inﬂexibility, altered rhythmicity in
substrate use, relative hyperphagia, and weight loss from
impaired nutrient storage, are presumably secondary to
diabetes.
DISCUSSION
The key ﬁnding of this study is that selective impairment of
insulin action in Glut4-expressing tissues, in the absence of
primary changes to liver and pancreatic b-cell function,
results in a murine model of T2D that faithfully recapit-
ulates the human disease. Further, the study identiﬁes
a heretofore ill-characterized entity that we propose to
name “Glut4 neuron,” as a site of insulin action. Our ﬁnd-
ings provide a solution to the conundrum on the site of
onset of insulin resistance, expand our understanding of
the neuroanatomy and cellular physiology of insulin action
in the CNS, and integrate the latter into the broader picture
of diabetes pathogenesis.
An integrated view of diabetes pathophysiology.
Identifying the sites of onset of insulin resistance is nec-
essary if we are to develop a rational approach to treating
this condition—a cornerstone of diabetes therapy (32).
Single InsR knockouts in individual tissues have been more
notable for what they failed to cause than for what they did
cause (33), as was the combined InsR ablation in muscle/
fat (6). Why is the InsR knockout in Glut4-expressing tis-
sues able to cause diabetes? Probably because, in addition
to the impairment of peripheral glucose disposal caused by
InsR knockout in muscle and fat, and unlike other models
of impaired InsR signaling in muscle (34) or fat (8), GIRKO
mice develop profound hepatic insulin resistance and b-cell
dysfunction. We favor the interpretation that the former is
due to impaired InsR signaling in Glut4 neurons (16,35,36),
with a possible contributory role of other factors, such as
FFA. Given that most hypothalamic neurons appear to be
Glut4-positive, it is likely that InsR signaling in these neu-
rons contributes to insulin’s demonstrated ability to control
HGP via the CNS (16,35,36). Our data do not imply that
InsR ablation in Glut4 neurons is the sole cause of diabetes.
Rather, they suggest that the combination of muscle, fat,
FIG. 6. Adipose and liver histology. Hematoxylin–eosin stain of BAT
(A) and epididymal WAT (B), and Oil red O stain (C) and periodic acid-
Schiff stain (D) of liver in 6-month-old male mice killed in the ad libi-
tum-fed state. Left: Control mice (WT). Middle: Nondiabetic GIRKO.
Right: Diabetic GIRKO mice. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
FIG. 7. Pancreatic islet morphology. Immunohistochemistry with anti-
bodies against insulin (brown) (A–C), Pdx1 (green) and insulin (red)
(D, E), glucagon (brown) (F–H), and Glut2 (brown) (I–K). Cell nuclei
are visualized by Hoechst stain (blue). Left: Control mice (WT). Middle:
Nondiabetic GIRKO. Right: Diabetic GIRKO mice. Representative
images are shown. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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706 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgFIG. 8. Energy homeostasis. A: Body weight of male WT and GIRKO mice. B: Body weight of 9-week-old male WT, nondiabetic GIRKO, and diabetic
GIRKO mice used for indirect calorimetry study. C: Cumulative food intake measured during calorimetry study normalized by total body weight.
D: Food intake per animal per day during the light and dark phases. Oxygen consumption normalized by body weight (E) or per animal (F).
G: Locomotor activity. H: Respiratory exchange ratio (RER). I: Substrate use was estimated on the basis of the assumptions that 1) protein ca-
tabolism is negligible and 2) RER of carbohydrate catabolism is 1 and RER of fat catabolism is 0.7. Percentage of carbohydrate use is calculated
with the formula %Carbohydrate = (RER 2 0.7) / 0.3. Data are mean 6 SEM. n = 7 (WT), 10 (nondiabetic GIRKO), and 3 (diabetic GIRKO). Mice
were habituated 24–36 h, and measurements were taken for 4–5 consecutive days. *P < 0.05, **P < 0.01, ***P < 0.01 between groups. ##P < 0.01 vs.
WT and nondiabetic GIRKO.
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euglycemic insulin resistance to diabetes.
It is also intriguing that InsR ablation in Glut4 neurons
did not affect total energy intake or expenditure, but rather
shifted circadian patterns of feeding and substrate use.
A large body of literature indicates that disruption of the
circadian clock in the CNS or peripheral tissues can lead
to insulin resistance, defects in insulin secretion, and other
manifestations of the metabolic syndrome (37,38). Further
studies will be necessary to determine whether alterations
in the circadian rhythm contribute to the cause of diabetes
in GIRKO mice.
Profound abnormalities of b-cell mass represent another
distinguishing feature of GIRKO mice from other models of
peripheral insulin resistance due to alterations of InsR
signaling (25,39). We speculate that the b-cell abnormality
is also secondary to impaired CNS control of endocrine
pancreatic function. But we cannot rule that other sites of
InsR ablation in GIRKO mice (e.g., vessel wall, exocrine
pancreas, or other as yet undiscovered locations) contribute
to this process. Nonetheless, the combined presence of cell-
autonomous mechanisms of insulin resistance (in muscle/
fat) and cell-nonautonomous mechanisms (in liver and
b-cell) in GIRKO mice indicates that Glut4-expressing tissues
play a direct role as metabolic targets for nutrient disposal
and storage, and a “sensing” role through which they are
able to affect liver and endocrine pancreatic function.
Glut4 neurons and Glut4 function in the CNS. The
presence of Glut4 in the CNS has long been a puzzle, partly
because of the presence of additional glucose transporters,
partly to lingering controversies as to its precise localiza-
tion (17,20,21,29,30,40–43), and partly to limited ability to
probe its function in this organ. Our study conclusively
demonstrates that neurons, not glia, are the site of Glut4
expression. Their distribution and morphology bespeak
heterogeneous functions, potentially including locomotor
and learning behaviors. In the hypothalamus, Glut4 neu-
rons could reasonably partake in glucose sensing, coun-
terregulation, and food intake (44). Their functions are
likely to extend beyond the functions of Glut4 itself. But it
is interesting that Glut4 ablation in the CNS impairs glu-
cose sensing and glucose tolerance (44). Brain glucose
sensing is important for counterregulation in response to
hypoglycemia and is altered by obesity and antecedent
hypoglycemia (45). Although most, if not all, glucose-
sensing neurons express both InsR and Glut4 (46), the
general view is that, under euglycemic conditions, glucose
sensing occurs independently of insulin, probably through
Glut3 and glucokinase (45). It is possible, however, that
InsR signaling leads to Glut4 translocation, thus increasing
local glucose concentrations at discrete sites within the
cell body or neuronal processes to levels that allow for
glucokinase activation, ATP generation, and closure of
KATP channels (47), with increased ﬁring of glucose-excited
neurons (48).
Insulin resistance remains a large unmet medical need,
and clinically effective agents that partly restore insulin
sensitivity remain limited to metformin and pioglitazone.
Because insulin signaling is pleiotropic and entails differ-
ent biological outcomes in different cell types, the rational
design of insulin sensitizers must rely on detailed knowl-
edge of the cellular sites and biochemical processes of
insulin resistance. GIRKO mice should prove widely useful
as a monogenic model of insulin-resistant diabetes, devoid
of the confounders generally associated with other com-
monly used models.
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